文献速递神经PET

疾病修饰治疗时代脑PET在阿尔茨海默病中的临床作用

Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-08-01

综述指出,美国食品药品监督管理局近期批准抗淀粉样蛋白单克隆抗体用于早期阿尔茨海默病患者后,脑影像在诊断、分诊和监测中重新受到重视。淀粉样蛋白和τ蛋白PET已改变对痴呆进展与分期的理解并影响临床管理,需标准化工作流程并将分子影像数据与其他疾病生物标志物整合。

要点

  • 淀粉样蛋白和τ蛋白PET已改变对痴呆进展与分期的理解,并影响临床管理。
  • 抗淀粉样蛋白单克隆抗体获批用于早期阿尔茨海默病后,脑影像用于诊断、分诊和监测的需求增加。
  • 需标准化工作流程,并将分子影像数据与其他疾病生物标志物整合。

核心结论

  • 淀粉样蛋白和τ蛋白PET在临床实践中作用不断演变,放射科医生需跟上临床实践进展以确保有效患者照护。

研究设计与样本

  • 综述,旨在向放射科医生更新淀粉样蛋白和τ蛋白PET在临床实践中的作用。

临床应用与阅片要点

  • 强调需要标准化工作流程,并将分子影像数据与其他疾病生物标志物整合。
  • 讨论淀粉样蛋白和τ蛋白PET对诊断和治疗决策的影响,以及报销和人力容量的挑战。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060. Amyloid and τ accumulation underpin our understanding of the pathophysiology of AD, with the abnormal accumulation of these proteins leading to neurodegeneration. With the recent approval of antiamyloid monoclonal antibody therapies for patients with early-stage Alzheimer disease by the Food and Drug Administration, there is renewed energy and focus on brain imaging for diagnosis, triage, and monitoring of patients with neurodegenerative disease. Furthermore, PET imaging of amyloid and τ has revolutionized our understanding of dementia progression and staging, and influences patient management in the clinical setting. We aim to update radiologists on the evolving role of amyloid and τ PET in clinical practice, emphasizing the need for standardized workflows and the integration of molecular imaging data with other disease biomarkers. We also discuss the clinical implications of amyloid and τ PET, including their impact on diagnosis and treatment decisions, as well as the challenges of reimbursement and workforce capacity. With recent shifts in the AD management landscape, it is crucial for radiologists to keep abreast of recent advances in clinical practice, thereby ensuring effective patient care.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Franceschi AM, Keir G, Benzinger TLS, et al. Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies. AJNR Am J Neuroradiol. 2025. PMID: 40639970. doi:10.3174/ajnr.A8738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。